Our Pipeline and Its Potential
Beyond Air Active Pipeline & Market Size
| Product | Indication | Development Status |
Key Dates* | US Sales Potential** |
Worldwide Sales Potential** |
|---|---|---|---|---|---|
| LungFitPH (Pulmonary Hypertension) |
In-Hospital use for PPHN and cardiac surgery (country specific) | Commercial system in development | FDA PMA filing 1Q20 US Launch 2H20 |
>$300m | >$600m |
| LungFitBRO (Bronchiolitis) |
Bronchiolitis | Pilot Phase | Pivotal Study expected during 2020/2021 Winter Launch 2022* |
>$500m Beyond Air to commercialize |
>$1.2b |
| LungFitNTM (Severe Lung Infections) |
NTM (nontuberculous mycobacteria) |
13 patients treated 2nd pilot study to have higher ppm NO and MAC infection |
2020 start for at home pilot study with self-administration Launch 2024* |
>$1b | >$2.5b |
*All dates are based on projections and appropriate financing, anticipated first launch on global basis pending appropriate regulatory approvals
**All figures are Company estimates for peak year sales: Global Sales Potential includes US Sales Potential
Beyond Air Inactive* Pipeline & Status
All Programs Below are Intended for Patients to Self-Administer at Home
| Product | Indication | Development Status* |
Worldwide Sales Potential** |
|---|---|---|---|
| LungFit PA | pseudomonas aeruginosa | Pilot study initiation anticipated in 2021 | Multi Billion $ Opportunities |
| LungFit COPD (Chronic Obstructive Pulmonary Disease) |
Exacerbation caused by any type of infection (treatment and prevention) |
Proof of concept initiation anticipated in 2021 | |
| LungFit PAH | At-Home Use | Proof of concept initiation anticipated in 2022 | |
| LungFit CF (Cystic Fibrosis) |
Acute infections and Chronic Therapy | Trials anticipated to begin in 2022 |
*Development of this pipeline is conditional on obtaining additional financing.
**All figures are Company estimates for peak year sales: Global Sales Potential includes US Sales Potential